Tariffs on meds would harm American competitiveness, industry and patients, say PhRMA
Pharmaceutical and Research Manufacturers of America (PhRMA) yesterday submitted comments to the US Department of Commerce on its Section 232 investigation of pharmaceuticals and pharmaceutical ingredients imported to the USA.
The US lobby group said that tariffs on the biopharmaceutical industry would threaten continued investment and medical progress. Every dollar spent on tariffs is a dollar that can’t be spent on developing tomorrow’s treatments and cures or on US manufacturing.
America’s innovative biopharmaceutical industry shares the Trump administration’s goal of bolstering American manufacturing and workers. The USA is the world leader in biopharmaceutical innovation and manufacturing and companies have recently announced hundreds of billions of dollars in additional investments in America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze